Ed Arce
Stock Analyst at WestPark Capital
(3.80)
# 670
Out of 5,154 analysts
376
Total ratings
46.2%
Success rate
9.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $13.54 | +106.79% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $27.24 | +10.13% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.55 | +8,416.13% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.60 | +1,036.36% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.11 | +743.88% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.27 | +490.55% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $6.13 | +112.07% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $3.12 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.87 | +591.64% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.98 | +902.87% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $28.27 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.35 | +17,677.78% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.33 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.41 | +491.50% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $86.30 | -16.57% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $432.83 | -6.43% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.19 | -11.15% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $21.25 | +347.06% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.53 | +10.38% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $29.86 | +60.75% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $42.82 | -82.48% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.17 | +2,921.15% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.32 | -9.22% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $39.07 | -36.01% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.11 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.98 | -78.78% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $37.29 | -43.68% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.89 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $13.54
Upside: +106.79%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $27.24
Upside: +10.13%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.55
Upside: +8,416.13%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.60
Upside: +1,036.36%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.11
Upside: +743.88%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.27
Upside: +490.55%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $6.13
Upside: +112.07%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.12
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.87
Upside: +591.64%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.98
Upside: +902.87%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $28.27
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $1.35
Upside: +17,677.78%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.41
Upside: +491.50%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $86.30
Upside: -16.57%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $432.83
Upside: -6.43%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.19
Upside: -11.15%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $21.25
Upside: +347.06%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.53
Upside: +10.38%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $29.86
Upside: +60.75%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $42.82
Upside: -82.48%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.17
Upside: +2,921.15%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.32
Upside: -9.22%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $39.07
Upside: -36.01%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $15.11
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.98
Upside: -78.78%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $37.29
Upside: -43.68%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.89
Upside: -